Halozyme posts strong Q1 growth with major shareholder returns. The biopharmaceutical company reported 42% revenue growth and announced a $1 billion share buyback program, signaling confidence in its financial position. ENHANZE royalties are projected to exceed $1 billion in 2026, driven by increased adoption of the company's hyaluronidase technology across multiple therapeutic areas. Management reaffirmed full-year 2026 guidance despite adjusting Hypercon Phase I timing. The buyback demonstrates management's belief that shares are undervalued at current levels. This combination of strong operational performance and aggressive capital returns positions Halozyme well for sustained shareholder value creation.
Post from MarketNews_en
Log in to interact with content.